tiprankstipranks
Trending News
More News >
Shanghai Kindly Medical Instruments Co., Ltd. Class H (HK:1501)
:1501
Hong Kong Market
Advertisement

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) AI Stock Analysis

Compare
2 Followers

Top Page

HK:1501

Shanghai Kindly Medical Instruments Co., Ltd. Class H

(1501)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
HK$35.00
▲(13.42% Upside)
Shanghai Kindly Medical Instruments Co., Ltd. Class H has a solid overall stock score driven primarily by strong financial performance, particularly in revenue growth and profitability margins. The technical analysis indicates some short-term weakness, while the valuation suggests moderate attractiveness. The absence of earnings call and corporate events data means these factors did not influence the score.

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company DescriptionShanghai Kindly Medical Instruments Co., Ltd. Class H (1501) is a leading manufacturer and supplier in the healthcare industry, specializing in the production of high-quality medical instruments and devices. The company operates primarily in the sectors of surgical instruments, medical consumables, and healthcare solutions, providing innovative products that cater to hospitals, clinics, and healthcare professionals. With a strong focus on research and development, Shanghai Kindly Medical Instruments aims to enhance patient care through advanced technology and quality assurance in its offerings.
How the Company Makes MoneyThe company generates revenue through the sale of its medical instruments and devices, which are distributed to healthcare facilities both domestically and internationally. Key revenue streams include direct sales of surgical instruments, medical consumables, and specialized healthcare solutions. Additionally, the company may engage in partnerships with healthcare institutions and distributors, which can enhance its market reach and sales volume. Factors contributing to its earnings include a robust product portfolio, continuous innovation, and compliance with international quality standards, which help to build trust and reliability in its offerings.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary
Shanghai Kindly Medical Instruments Co., Ltd. Class H shows strong financial performance with robust revenue growth and profitability margins. The balance sheet is solid with low leverage and a strong equity base, reducing financial risk. However, cash flow efficiency needs improvement, which slightly tempers the overall financial score.
Income Statement
85
Very Positive
Shanghai Kindly Medical Instruments Co., Ltd. Class H has demonstrated strong income statement performance with a consistent upward trajectory in revenue growth, showing an impressive revenue growth rate from 2023 to 2024 at 13.15%. Gross profit margin remains robust at approximately 63.11%, indicating effective cost management. The net profit margin also improved, reaching 22.53% in 2024, reflecting enhanced profitability. The company maintains healthy EBIT and EBITDA margins at 25.38% and 29.98%, respectively, showcasing operational efficiency. The key strength lies in sustained revenue growth and high profitability margins, although the company should monitor any future fluctuations in margins.
Balance Sheet
88
Very Positive
The balance sheet of Shanghai Kindly Medical Instruments Co., Ltd. Class H reveals a strong financial position with an equity ratio of 78.51% in 2024, indicating a solid equity base relative to total assets. The debt-to-equity ratio remains low at 0.14, suggesting minimal leverage and reduced financial risk. Return on equity improved to 10.82%, reflecting enhanced returns for shareholders. The company benefits from a strong equity position and low leverage, which contributes to financial stability and mitigates risk.
Cash Flow
70
Positive
Cash flow analysis for Shanghai Kindly Medical Instruments Co., Ltd. Class H shows areas for improvement. The operating cash flow to net income ratio is low due to operating cash flow being unavailable in 2024. Free cash flow remains a concern with fluctuations observed in prior years, indicating potential challenges in cash generation from operations. However, the company has managed to maintain a positive free cash flow in earlier periods, suggesting potential for recovery in cash flow generation. Focus should be placed on enhancing cash flow efficiency.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue851.95M752.84M585.88M464.68M358.43M
Gross Profit537.66M438.07M332.49M275.75M234.41M
EBITDA255.43M225.88M159.99M168.81M143.23M
Net Income191.91M156.46M131.71M142.96M121.35M
Balance Sheet
Total Assets2.26B2.03B1.83B1.62B1.42B
Cash, Cash Equivalents and Short-Term Investments554.51M434.40M528.27M640.55M941.59M
Total Debt243.69M94.78M48.83M13.40M1.73M
Total Liabilities473.39M351.25M273.23M183.63M95.04M
Stockholders Equity1.77B1.65B1.51B1.40B1.31B
Cash Flow
Free Cash Flow59.80M-53.05M-62.75M-205.07M7.92M
Operating Cash Flow225.54M178.15M180.46M72.76M95.71M
Investing Cash Flow-187.31M-283.81M-316.18M-268.08M-221.87M
Financing Cash Flow56.97M8.06M9.72M-31.07M-27.95M

Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price30.86
Price Trends
50DMA
31.68
Negative
100DMA
28.15
Positive
200DMA
27.61
Positive
Market Momentum
MACD
-0.15
Positive
RSI
48.40
Neutral
STOCH
78.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Positive. The current price of 30.86 is below the 20-day moving average (MA) of 30.92, below the 50-day MA of 31.68, and above the 200-day MA of 27.61, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 48.40 is Neutral, neither overbought nor oversold. The STOCH value of 78.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1501.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
83
Outperform
€10.60B17.4523.40%2.91%6.51%4.85%
74
Outperform
€4.89B10.2917.42%3.80%6.87%18.37%
73
Outperform
HK$5.43B26.2510.31%0.97%14.06%3.02%
72
Outperform
€2.15B13.943.76%6.71%21.39%-0.57%
66
Neutral
HK$18.25B31.5724.57%0.89%13.58%24.59%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
€282.36M-8.46%45.13%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
30.86
2.36
8.28%
HK:9997
Kangji Medical Holdings Limited
8.97
3.34
59.24%
HK:1358
PW Medtech Group Ltd.
1.46
0.46
45.85%
HK:0876
Kaisa Health Group Holdings Limited
0.06
0.03
93.10%
HK:3600
Modern Dental Group Limited
5.23
1.86
55.01%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
38.02
22.79
149.64%

Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events

Shanghai Kindly Medical Instruments Establishes Huaige Guangtai Fund for Medical Device Investments
Aug 6, 2025

Shanghai Kindly Medical Instruments Co., Ltd. has entered into a Partnership Agreement to establish the Huaige Guangtai Fund, with a capital commitment of up to RMB110 million. This fund aims to achieve returns through equity investments in medical device companies, potentially strengthening the company’s market position and investment portfolio.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments to Discuss Share Issuance Mandate at 2025 EGM
Jul 31, 2025

Shanghai Kindly Medical Instruments Co., Ltd. has announced the convening of its first extraordinary general meeting of 2025 to discuss a special resolution. The resolution seeks to grant the Board a general mandate to issue additional Domestic and/or H Shares, not exceeding 20% of the total issued shares, to enhance the company’s capital structure and support its growth strategies.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai INT Medical Instruments Updates Supervisor Emoluments
Jun 20, 2025

Shanghai INT Medical Instruments Co., Ltd. has released a supplemental announcement detailing the emoluments paid to its supervisors from 2019 to 2024. The announcement clarifies that the emoluments were paid in their capacity as employees of the group, not as supervisors, and does not alter any other information in the company’s annual reports.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai INT Medical Instruments Co., Ltd. Announces AGM Results and Board Appointments
May 23, 2025

Shanghai INT Medical Instruments Co., Ltd., a company incorporated in China, held its annual general meeting for 2024 on May 23, 2025. The meeting, chaired by Dr. Liang Dongke, resulted in the approval of all resolutions, including the re-election and appointment of directors and supervisors, and the election of the chairman for the fourth session of the board and supervisory committee. The unanimous approval of the company’s reports and financial statements reflects strong shareholder support and positions the company for continued stability and governance.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments Announces Board Composition
May 23, 2025

Shanghai Kindly Medical Instruments Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and decision-making processes, which could influence stakeholders’ perspectives on the company’s future operations.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments to Acquire Controlling Stake in Target Company
May 21, 2025

Shanghai Kindly Medical Instruments Co., Ltd., a company incorporated in the People’s Republic of China, has entered into a Formal Acquisition Agreement to acquire a controlling stake in a target company. The acquisition involves purchasing 81.83% equity interest in the target company for approximately RMB512.84 million, with Shanghai Kindly Medical Instruments acquiring a 51.70% controlling stake. This transaction will result in the target company becoming a non-wholly owned subsidiary, and further capital injection is planned. The acquisition is classified as a discloseable transaction under the Listing Rules, requiring reporting and announcement.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 16, 2025